pfizer glp-1 news pulls out of race after safety concerns Pfizer's Appetite for More Obesity

Longer medication persistence among patients through lifestyle change support helps to offset the reduction in pharma revenue due to narrower clinical criteria and lower patient volumethis is critical so that pharma companies are incentivized to maintain meaningful rebates for employers

Comprehensive animal studies and well-designed clinical trials will be essential to transition these innovative materials from bench to bedside

Never ignore the symptoms: your safety is the most important thing

Walgreens new policy adds about six layers of fuckery to the workflow for all the GLP-1s. Walgreens did not respond to a request for comment

Pattern across both trials Nausea, vomiting, and diarrhea peaked during dose escalation and tapered during maintenance